www.fdanews.com/articles/177563-nichi-iko-picks-up-sagent-pharmaceuticals
Nichi-Iko Pharmaceutical has entered into an agreement to acquire Sagent Pharmaceuticals for nearly $736 million.
The acquisition combines Nichi-Iko’s biosimilar portfolio and Sagent’s line of injectables.
Currently, no operational changes are expected for Sagent Pharmaceuticals. — Anisa JibrellÂ